You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 6,562,957


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,562,957
Title: Genomic sequence encoding endoglin and fragments thereof
Abstract:A method of diagnosing hereditary haemorrhagic telangiectasia (HHT) which includes the steps of: obtaining a sample of genomic DNA from a patient or fetus; and determining whether the DNA contains a mutation in a gene encoding endoglin, betaglycan, TGF-.beta. type I receptor (RI), TGF-.beta. type II receptor (RII), or TGF-.beta./activin type I receptor (TSR-I), such a mutation being an indication that the patient or fetus bears a gene making the patient or fetus susceptible to HHT.
Inventor(s): Letarte; Michelle (Toronto, CA), Marchuk; Douglas A. (Chapel Hill, NC), McAllister; Kimberly (Durham, NC)
Assignee: HSC Research & Development Limited Partnership (CA) Duke University (Durham, NC)
Application Number:09/506,859
Patent Claims:1. An isolated DNA molecule consisting of a human genomic DNA sequence encoding endoglin, which is associated with hereditary haemorrhagic telangiectasia, wherein the human genomic DNA sequence: (a) encodes a protein with the amino acid sequence of SEQ ID NO:2 wherein the protein retains one or more biological properties of the endoglin encoded by the DNA contained in cosmid 21c10, which has been deposited with the American Type Culture Collection and assigned Accession Number 98685; (b) comprises fourteen exons and their intervening introns, wherein the coding sequence of the genomic sequence comprises SEQ ID NO: 1.

2. A pair of PCR primers comprising a first oligonucleotide 14-50 nucleotides in length having a nucleotide sequence identical to that of a 14-50 nucleotide segment of a first strand of endoglin genomic DNA within the cosmid 21c10, which has been deposited with the American Type Culture Collection and assigned Accession Number 98695, and which encodes a protein with the amino acid sequence of SEQ ID NO: 2, said segment of said first strand of endoglin genomic DNA being within an intron of said genomic DNA, and a second oligonucleotide that has a sequence identical to that of 14-50 nucleotide segment of the strand complementary to said first strand of endoglin genomic DNA, said segment of said complementary strand being within (a) a second intron of the genomic DNA, (b) the 5' untranslated region immediately adjacent to the translation start signal of the genomic DNA, or (c) the 3' untranslated region immediately adjacent to the termination signal of the genomic DNA, provided that said pair of primers is selected to prime the PCR amplification of a single exon of said genomic DNA.

3. A vector comprising the isolated DNA molecule of claim 1.

Details for Patent 6,562,957

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 06/04/1986 ⤷  Try a Trial 2014-11-29
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Try a Trial 2014-11-29
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b Injection 103132 ⤷  Try a Trial 2014-11-29
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.